News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bristol-Myers Squibb Company (BMY) and Otsuka America Pharmaceutical, Inc. Release: Four-Year Data From Phase 3 DASISION Trial Comparing Sprycel┬« (dasatinib) To Imatinib In First-Line Treatment Of Adults With Ph+ CP-CML Presented At Annual Meeting Of The American Society of Hematology



12/10/2013 6:56:26 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Bristol-Myers Squibb Company (NYSE:BMY) and Otsuka America Pharmaceutical, Inc. today announced four-year follow-up data from the Phase 3 DASISION study of Sprycel® (dasatinib) 100 mg once daily vs. imatinib (400 mg daily) in the first-line treatment of adults with Philadelphia chromosome-positive (Ph+) chronic phase chronic myeloid leukemia (CP-CML).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES